Theseus Pharmaceuticals has launched from under the wing of healthcare fund manager OrbiMed with a $100 million series B financing and data to show that the new biotech’s gastrointestinal tumor ...

It’s been a wild November for Theseus Pharmaceuticals. Just a couple of weeks ago, the biotech laid off almost three-quarters of its staff. Days later, the company received offers from two sets of ...

Viewers follow Theseus’ major adventures, including his famous journey into the Labyrinth to confront the Minotaur.

Theseus Pharmaceuticals is being acquired by Concentra Biosciences at a cash price of $4.05 per share. Shareholders will also receive a contingent value right that includes 80% of the net proceeds ...

Theseus Pharmaceuticals experienced significant losses after discontinuing its lead program, leaving it with a market cap of half of its current assets. THRX is now focusing on developing a ...

Theseus Pharmaceuticals Inc. THRX shares plummeted after hours Thursday after the biotech drug maker discontinued enrolling patients in the study of a cancer drug it no longer intend to develop.

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More The fictional Voltron robot (from the animated science fiction show of ...

Games can often change drastically during development, moving away from the creators' original vision and toward something potentially even better. The developers of Hades recently gave an interview ...

The UK Defence Science and Technology Laboratory (Dstl) conducted a public demonstration of the Project Theseus Joint Tactical Autonomous Resupply and Replenishment (JTARR) capability on 12 August, ...